APOB rs673548 — Intronic Variant Linked to Cardiovascular and Lipid Risk
Apolipoprotein B (APOB) is the primary protein component of low-density lipoprotein (LDL) particles. Every LDL particle contains exactly one APOB-100 molecule, which acts as the structural backbone and also serves as the ligand that allows LDL to bind LDL receptors on liver and other cells. Higher plasma APOB concentrations — even when LDL-C appears normal — are a direct measure of atherogenic particle burden 11 Glavinovic et al. Physiological Bases for the Superiority of Apolipoprotein B Over LDL Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Assoc, 2022.
rs673548 is an intronic variant located 79 nucleotides upstream of exon 3697 in NM_000384.3 (c.3697-79C>T in transcript notation; G>A on the plus strand at chr2:21014672). It does not change the APOB amino acid sequence. Instead, intronic variants at this position may influence mRNA splicing efficiency, pre-mRNA processing, or serve as a tag for nearby regulatory variants affecting APOB expression levels.
The Mechanism
As an intron variant, rs673548 itself does not alter the APOB-100 protein. Its
functional significance likely derives from linkage disequilibrium22 linkage disequilibrium
LD is the tendency for nearby alleles to be inherited together; a marker SNP can tag an unobserved causal variant
with functional variants elsewhere in the APOB locus, or from direct effects on
intronic splicing regulatory elements. The APOB locus harbors multiple variants in
strong LD — rs673548, rs676210 (missense, Pro2739Leu), rs1042034 (missense,
Ser4338Ile), and rs693 — that are often inherited together as a haplotype block.
The cardiovascular associations attributed to rs673548 may partly reflect the
combined effect of this haplotype rather than rs673548 acting alone.
The Evidence
A 2022 case-control study33 2022 case-control study
Aceves-Ramírez et al. Analysis of the APOB gene and apolipoprotein B serum levels in a Mexican population with acute coronary syndrome. Genetics Research, 2022
enrolled 300 acute coronary syndrome (ACS) patients and 300 matched controls in a
Mexican population. rs673548 showed a statistically significant allelic difference
between groups (OR=1.33, p=0.030). The study also identified a risk haplotype
(TAGT, encompassing rs1469513, rs673548, rs676210, and rs1042034) with OR=2.14
(95% CI 1.50–3.04, p<0.001). Notably, APOB serum levels did not differ significantly
by genotype in either group, suggesting the variant tags a structural haplotype
rather than directly altering circulating apoB protein concentration.
A 2017 case-control study in Chinese Han males44 2017 case-control study in Chinese Han males
Zhou et al. Variants in the APOB gene associated with ischemic stroke susceptibility in Chinese Han male population. Oncotarget, 2017
(325 ischemic stroke patients, 399 healthy controls) found the G allele of rs673548
significantly associated with increased ischemic stroke risk (OR=1.28, 95% CI
1.02–1.62, p=0.034). In the same population, the log-additive model gave an OR
of 1.27 per G allele copy. This study was restricted to males and a single Chinese
Han cohort, which limits generalizability.
A complementary haplotype analysis55 haplotype analysis
Xiao et al. Association analysis of APO gene polymorphisms with ischemic stroke risk: a case-control study in Chinese Han population. Oncotarget, 2017
(488 cases, 503 controls) identified strong linkage involving rs673548 with rs1042034,
rs676210, and rs693 in a block associated with stroke risk, consistent with the
haplotype model.
Practical Actions
The G allele is the reference allele and is most common in Europeans (~79%) and Africans (~79%), but notably less frequent in East Asians (~27%). The A allele — minor in most populations but major in East Asians (~73%) — appears modestly protective in the available studies. Effect sizes are modest (OR ~1.28–1.33 for G), and current evidence comes from relatively small, population-specific case-control studies. This variant should be interpreted in the context of the full APOB haplotype and overall cardiovascular risk profile.
For GG carriers, the most evidence-supported strategies are monitoring serum ApoB directly (rather than relying solely on LDL-C), and ensuring LDL-C targets are met with clinical guidance. Statin therapy lowers APOB-containing lipoprotein particles regardless of rs673548 genotype, so this SNP does not alter statin eligibility — but GG carriers with borderline cardiovascular risk may benefit from earlier lipid panel monitoring that includes direct ApoB measurement.
Interactions
rs673548 sits in a haplotype block with rs676210 (p.Pro2739Leu), rs1042034 (p.Ser4338Ile), and rs693 — these variants are often co-inherited. The combined TAGT haplotype carried substantially higher ACS risk (OR=2.14) than rs673548 alone (OR=1.33), suggesting the variant's risk signal amplifies in the context of this linked block. Carriers of multiple LDL-raising variants across the TRIB1, GCKR, and APOB loci face cumulative atherogenic risk; a lipid panel that includes direct ApoB quantification (target <80 mg/dL for high cardiovascular risk) is more informative than LDL-C alone in this setting.